Side-by-side comparison of AI visibility scores, market position, and capabilities
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Largest US for-profit hospital network with ~190 hospitals; $70.7B FY2024 revenue; AI clinical decision support reducing preventable mortality; Sun Belt demographics advantage; NYSE: HCA.
HCA Healthcare is the largest for-profit hospital system in the United States, founded in 1968 by Jack Massey, Dr. Thomas Frist Sr., and Dr. Thomas Frist Jr. in Nashville, Tennessee, where it remains headquartered and trades on NYSE (HCA). The company operates approximately 190 hospitals and 2,400 ambulatory care sites—including surgery centers, physician clinics, and urgent care facilities—across 20 U.S. states and the United Kingdom, serving over 37 million patients annually. For FY2024, HCA generated approximately $70.7 billion in revenues under CEO Samuel Hazen, continuing a multi-year growth trajectory driven by hospital volume recovery, acuity mix improvement, and strategic investments in ambulatory care that intercept patients in lower-cost settings before they require inpatient hospitalization.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.